NEW YORK (GenomeWeb News) – Investment bank UBS yesterday upgraded Cepheid’s shares from “Neutral” to “Buy” based on the current valuation of the stock.
 
Analyst Derik De Bruin noted in a research note that Cepheid’s stock is down 40 percent from its peak of $32.83 in late January and February, “due in part to insider selling, conflicting views on the importance of universal MRSA testing in the medical literature, and reimbursement confusion.” He wrote that the stock’s current valuation is “compelling.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.